Cytoreductive surgery
From Wikipedia, the free encyclopedia
Cytoreductive surgery (CRS) is a surgical procedure that aims to reduce the amount of cancer cells in the abdominal cavity for patients with tumors that have spread intraabdominally (peritoneal carcinomatosis). The ultimate goal of CRS is to achieve the complete gross resection (CGR) in other words to remove all visible disease from the abdominal cavity. It is often used to treat ovarian cancer but can also be used for other abdominal malignancies.
CRS is often used in combination with hyperthermic intraperitoneal chemotherapy (HIPEC); for some cancer diagnoses it considerably increases life expectancy and reduces the rate of cancer recurrence.
Its main developer was Paul Sugarbaker, who is known for the development of cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy,[1] or HIPEC, a treatment alternately referred to as the Sugarbaker Procedure.[2][3]